Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$58.20K$58.20Kderived+151.4% vs Q4 2015 Net Income$135.28K$135.28KderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$35,731N/M Operating Incomederived$137,229N/M Operating Cash Flowderived-$7,681N/M Margins · derivedGross margin61.4%+128.2 pt vs Q4 2015
Operating margin235.8%+1744.4 pt vs Q4 2015
Net margin232.4%+1749.9 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 31, 2017 · 90 d after period end